新冠肺炎中度低氧血症患者的俯卧位通气:多中心实用随机试验(COVID-PRONE)
COVID-PRONE是一项在加拿大和美国15家医院开展的多中心实用随机试验,纳入需补充氧气(吸入氧浓度最高50%)且能独立俯卧的新冠肺炎患者,1:1随机分为俯卧位组和标准治疗组。试验因预设主要结局无效而提前终止。主要复合终点(院内死亡、机械通气或呼吸衰竭恶化)在俯卧位组18例(14%)与标准治疗组17例(14%)间相似(OR 0.92,95%CI 0.44–1.92);72小时后氧饱和度与吸入氧浓度比值变化两组也相似。作者认为,多层面干预增加俯卧位未改善结局,但置信区间宽不能排除获益或危害,且俯卧位依从性差。
要点
- 非危重新冠肺炎低氧血症患者中,俯卧位组主要复合终点18例(14%)vs 标准治疗组17例(14%),OR 0.92(95%CI 0.44–1.92),无统计学显著差异。
- 试验因预设主要结局无效而提前终止,95%CI宽(0.44–1.92),不能排除俯卧位的获益或危害。
- 前72小时内俯卧位组中位俯卧时间仅6小时(IQR 1.5–12.8),对照组0小时(IQR 0–2),依从性差。
- 72小时后氧饱和度与吸入氧浓度比值变化在俯卧位组与标准治疗组间相似。
- 作者建议后续俯卧位试验应开发提高清醒俯卧位依从性的策略。
适用人群与场景
- 实验室确诊或临床高度疑似新冠肺炎、需要补充氧气(吸入氧浓度最高50%)、能通过口头指令独立俯卧的住院患者。
- 非危重住院患者;随机化时距入院中位时间1天,中位年龄56岁(IQR 45–65),女性89例(36%),222例(90%)经鼻导管吸氧。
处置流程与药物剂量
- 俯卧位组接受俯卧位干预(即指导患者在卧床时俯卧),对照组接受标准治疗(即不指导患者采取俯卧位)。
研究设计与关键结果
- 多中心实用随机试验,15家医院(加拿大和美国),2020年5月至2021年5月,评估570例,随机257例,纳入分析248例。
- 主要复合终点为院内死亡、机械通气或呼吸衰竭恶化(定义为需要吸入氧浓度至少60%持续至少24小时);俯卧位组18例(14%)vs 标准治疗组17例(14%),OR 0.92(95%CI 0.44–1.92)。
- 前72小时内俯卧位组中位俯卧时间6小时(IQR 1.5–12.8)vs 对照组0小时(IQR 0–2)。
- 72小时后氧饱和度与吸入氧浓度比值变化在俯卧位组与标准治疗组间相似。
- 试验因预设主要结局无效而提前终止。
证据类型、等级与局限
- 证据类型:多中心实用随机临床试验。
- 局限:试验因预设主要结局无效而提前终止;95%CI宽(0.44–1.92),不能 definitively 排除获益或危害;俯卧位依从性差。
对床旁实践的改变
- 作者认为,在因新冠肺炎住院的非危重低氧血症患者中,多层面干预增加俯卧位未改善结局。
- 作者认为,宽置信区间不能 definitively 排除获益或危害。
- 作者建议,后续俯卧位试验应开发提高清醒俯卧位依从性的策略。
指南或共识出处
- ClinicalTrials.gov NCT04383613
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: To assess the effectiveness of prone positioning to reduce the risk of death or respiratory failure in non-critically ill patients admitted to hospital with covid-19.
DESIGN: Multicentre pragmatic randomised clinical trial.
SETTING: 15 hospitals in Canada and the United States from May 2020 until May 2021.
PARTICIPANTS: Eligible patients had a laboratory confirmed or a clinically highly suspected diagnosis of covid-19, needed supplemental oxygen (up to 50% fraction of inspired oxygen), and were able to independently lie prone with verbal instruction. Of the 570 patients who were assessed for eligibility, 257 were randomised and 248 were included in the analysis.
INTERVENTION: Patients were randomised 1:1 to prone positioning (that is, instructing a patient to lie on their stomach while they are in bed) or standard of care (that is, no instruction to adopt prone position).
MAIN OUTCOME MEASURES: The primary outcome was a composite of in-hospital death, mechanical ventilation, or worsening respiratory failure defined as needing at least 60% fraction of inspired oxygen for at least 24 hours. Secondary outcomes included the change in the ratio of oxygen saturation to fraction of inspired oxygen.
RESULTS: The trial was stopped early on the basis of futility for the pre-specified primary outcome. The median time from hospital admission until randomisation was 1 day, the median age of patients was 56 (interquartile range 45-65) years, 89 (36%) patients were female, and 222 (90%) were receiving oxygen via nasal prongs at the time of randomisation. The median time spent prone in the first 72 hours was 6 (1.5-12.8) hours in total for the prone arm compared with 0 (0-2) hours in the control arm. The risk of the primary outcome was similar between the prone group (18 (14%) events) and the standard care group (17 (14%) events) (odds ratio 0.92, 95% confidence interval 0.44 to 1.92). The change in the ratio of oxygen saturation to fraction of inspired oxygen after 72 hours was similar for patients randomised to prone positioning and standard of care.
CONCLUSION: Among non-critically ill patients with hypoxaemia who were admitted to hospital with covid-19, a multifaceted intervention to increase prone positioning did not improve outcomes. However, wide confidence intervals preclude definitively ruling out benefit or harm. Adherence to prone positioning was poor, despite multiple efforts to increase it. Subsequent trials of prone positioning should aim to develop strategies to improve adherence to awake prone positioning.
STUDY REGISTRATION: ClinicalTrials.gov NCT04383613.
参考来源
- Fralick M, Colacci M, Munshi L, et al. Prone positioning of patients with moderate hypoxaemia due to covid-19: multicentre pragmatic randomised trial (COVID-PRONE). BMJ. 2022. PMID: 35321918. doi:10.1136/bmj-2021-068585
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。